U.S. markets closed

Jounce Therapeutics, Inc. (JNCE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
1.85000.0000 (0.00%)
At close: 04:00PM EDT
1.8400 -0.01 (-0.54%)
After hours: 05:49PM EDT

Jounce Therapeutics, Inc.

780 Memorial Drive
Cambridge, MA 02139
United States
857 259 3840

Full Time Employees141

Key Executives

NameTitlePayExercisedYear Born
Dr. Richard Murray Ph.D.Pres, CEO & Director887.4kN/A1959
Mr. Hugh M. ColeChief Operating Officer607.44kN/A1965
Dr. Elizabeth G. Trehu M.D.Chief Medical Officer639.6kN/A1960
Dr. James Patrick Allison Ph.D.FounderN/AN/AN/A
Dr. Thomas F. Gajewski M.D., Ph.D.FounderN/AN/AN/A
Dr. Robert D. Schreiber Ph.D.FounderN/AN/AN/A
Dr. Drew Mark Pardoll M.D., Ph.D.FounderN/AN/AN/A
Dr. Padmanee Sharma M.D., Ph.D.FounderN/AN/AN/A
Dr. Louis M. Weiner M.D.FounderN/AN/A1952
Ms. Kimberlee Cobleigh Drapkin CPA, CPACFO & TreasurerN/AN/A1968
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy. In addition, its preclinical products are JTX-1484, a monoclonal antibody designed to reduce myeloid-mediated immune suppression; and JTX-2134, a monoclonal antibody designed to reduce myeloid-mediated immune suppression and activate T and NK cells. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Jounce Therapeutics, Inc.’s ISS Governance QualityScore as of March 30, 2023 is 7. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.